Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic

Sheldon Greer, Tieran Han, Cristina Dieguez, Nicola McLean, Rafael Saer, Isildinha Reis, Joe Levi, Victor E. Marquez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Enzymatic activity from tumor and adjacent normal tissue of 200 patients involving deoxycytidine kinase (dCK), uridine/cytidine kinase (U/CK), cytidine deaminase (CD) and deoxycytidylate deaminase (dCMPD) was quantified. Patients with brain (17), colon (24), and breast (30) tumors, 53, 67, and 73%, respectively, had an elevated T/N value (Specific Activity of tumor/ Specific Activity of normal tissue) involving dCK and dCMPD suggesting chemotherapy with 5-fluorodeoxycytidine (5-FdC) alone or in combination with thymidine plus deoxytetra-hydrouridine, or with the radiosensitizer, 5-chlorodeoxycytidine (5-CldC) plus tetrahydrouridine (H4U). Among patients with colon (19) and pancreatic tumors (40), 53 and 68%, respectively, displayed T/N values >4 for CD suggesting chemotherapy with 5-FdC, 4-N-methylamino-5-FdC, 5-trifluoromethyldeoxycytidine and radiosensitization with 5- CldC, 4-N-methylamino-5-CldC, 5-iododeoxycytidine and 5-bromodeoxycytidine. The percent of patients with tumors with a T/N value >4 for U/CK in lung (72), colon (23) and breast (28) was 47, 61 and 68, respectively, suggesting zebularine (plus thymidine) treatment for tumors involving gene silencing. Evidence is presented that the 4-N-alkylamino-dC substituted nucleosides and those with large 5-substitutions are activated only via CD to thymidine kinase (TK) using end-points of cytotoxicity and/or radiosensitization: H4U, the inhibitor of CD is an antagonist, cells with low CD or no TK are resistant to the analogs, the end points are indifferent to the dCK status of cells, they are poor substrates for dCK and good substrates for CD, whereas 5-FdC and 5-CldC are good substrates for both enzymes. The analogs present opportunities for Collateral Sensitivity for 5-azacytidine and gemcitabine resistant tumors.

Original languageEnglish (US)
Pages (from-to)250-264
Number of pages15
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pyrimidine Nucleosides
Cytidine Deaminase
Deoxycytidine Kinase
Radiotherapy
Uridine Kinase
Enzymes
Neoplasms
Colon
pyrimidin-2-one beta-ribofuranoside
Thymidine Kinase
gemcitabine
Thymidine
Bromodeoxycytidine
Tetrahydrouridine
DCMP Deaminase
Azacitidine
Drug Therapy
Gene Silencing
Nucleosides
Breast

Keywords

  • Activation of prodrugs
  • Chemotherapy
  • Cytidine deaminase
  • DCkinase
  • DCMPdeaminase
  • Pyrimidine nucleoside analogs
  • Radiosensitization
  • Uridine/cytidine kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Cancer Research

Cite this

Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic. / Greer, Sheldon; Han, Tieran; Dieguez, Cristina; McLean, Nicola; Saer, Rafael; Reis, Isildinha; Levi, Joe; Marquez, Victor E.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 17, No. 2, 01.02.2017, p. 250-264.

Research output: Contribution to journalArticle

Greer, Sheldon ; Han, Tieran ; Dieguez, Cristina ; McLean, Nicola ; Saer, Rafael ; Reis, Isildinha ; Levi, Joe ; Marquez, Victor E. / Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic. In: Anti-Cancer Agents in Medicinal Chemistry. 2017 ; Vol. 17, No. 2. pp. 250-264.
@article{09268b53ebde4a45bab3f4bfec250409,
title = "Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic",
abstract = "Enzymatic activity from tumor and adjacent normal tissue of 200 patients involving deoxycytidine kinase (dCK), uridine/cytidine kinase (U/CK), cytidine deaminase (CD) and deoxycytidylate deaminase (dCMPD) was quantified. Patients with brain (17), colon (24), and breast (30) tumors, 53, 67, and 73{\%}, respectively, had an elevated T/N value (Specific Activity of tumor/ Specific Activity of normal tissue) involving dCK and dCMPD suggesting chemotherapy with 5-fluorodeoxycytidine (5-FdC) alone or in combination with thymidine plus deoxytetra-hydrouridine, or with the radiosensitizer, 5-chlorodeoxycytidine (5-CldC) plus tetrahydrouridine (H4U). Among patients with colon (19) and pancreatic tumors (40), 53 and 68{\%}, respectively, displayed T/N values >4 for CD suggesting chemotherapy with 5-FdC, 4-N-methylamino-5-FdC, 5-trifluoromethyldeoxycytidine and radiosensitization with 5- CldC, 4-N-methylamino-5-CldC, 5-iododeoxycytidine and 5-bromodeoxycytidine. The percent of patients with tumors with a T/N value >4 for U/CK in lung (72), colon (23) and breast (28) was 47, 61 and 68, respectively, suggesting zebularine (plus thymidine) treatment for tumors involving gene silencing. Evidence is presented that the 4-N-alkylamino-dC substituted nucleosides and those with large 5-substitutions are activated only via CD to thymidine kinase (TK) using end-points of cytotoxicity and/or radiosensitization: H4U, the inhibitor of CD is an antagonist, cells with low CD or no TK are resistant to the analogs, the end points are indifferent to the dCK status of cells, they are poor substrates for dCK and good substrates for CD, whereas 5-FdC and 5-CldC are good substrates for both enzymes. The analogs present opportunities for Collateral Sensitivity for 5-azacytidine and gemcitabine resistant tumors.",
keywords = "Activation of prodrugs, Chemotherapy, Cytidine deaminase, DCkinase, DCMPdeaminase, Pyrimidine nucleoside analogs, Radiosensitization, Uridine/cytidine kinase",
author = "Sheldon Greer and Tieran Han and Cristina Dieguez and Nicola McLean and Rafael Saer and Isildinha Reis and Joe Levi and Marquez, {Victor E.}",
year = "2017",
month = "2",
day = "1",
doi = "10.2174/1871520616666161013145853",
language = "English (US)",
volume = "17",
pages = "250--264",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic

AU - Greer, Sheldon

AU - Han, Tieran

AU - Dieguez, Cristina

AU - McLean, Nicola

AU - Saer, Rafael

AU - Reis, Isildinha

AU - Levi, Joe

AU - Marquez, Victor E.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Enzymatic activity from tumor and adjacent normal tissue of 200 patients involving deoxycytidine kinase (dCK), uridine/cytidine kinase (U/CK), cytidine deaminase (CD) and deoxycytidylate deaminase (dCMPD) was quantified. Patients with brain (17), colon (24), and breast (30) tumors, 53, 67, and 73%, respectively, had an elevated T/N value (Specific Activity of tumor/ Specific Activity of normal tissue) involving dCK and dCMPD suggesting chemotherapy with 5-fluorodeoxycytidine (5-FdC) alone or in combination with thymidine plus deoxytetra-hydrouridine, or with the radiosensitizer, 5-chlorodeoxycytidine (5-CldC) plus tetrahydrouridine (H4U). Among patients with colon (19) and pancreatic tumors (40), 53 and 68%, respectively, displayed T/N values >4 for CD suggesting chemotherapy with 5-FdC, 4-N-methylamino-5-FdC, 5-trifluoromethyldeoxycytidine and radiosensitization with 5- CldC, 4-N-methylamino-5-CldC, 5-iododeoxycytidine and 5-bromodeoxycytidine. The percent of patients with tumors with a T/N value >4 for U/CK in lung (72), colon (23) and breast (28) was 47, 61 and 68, respectively, suggesting zebularine (plus thymidine) treatment for tumors involving gene silencing. Evidence is presented that the 4-N-alkylamino-dC substituted nucleosides and those with large 5-substitutions are activated only via CD to thymidine kinase (TK) using end-points of cytotoxicity and/or radiosensitization: H4U, the inhibitor of CD is an antagonist, cells with low CD or no TK are resistant to the analogs, the end points are indifferent to the dCK status of cells, they are poor substrates for dCK and good substrates for CD, whereas 5-FdC and 5-CldC are good substrates for both enzymes. The analogs present opportunities for Collateral Sensitivity for 5-azacytidine and gemcitabine resistant tumors.

AB - Enzymatic activity from tumor and adjacent normal tissue of 200 patients involving deoxycytidine kinase (dCK), uridine/cytidine kinase (U/CK), cytidine deaminase (CD) and deoxycytidylate deaminase (dCMPD) was quantified. Patients with brain (17), colon (24), and breast (30) tumors, 53, 67, and 73%, respectively, had an elevated T/N value (Specific Activity of tumor/ Specific Activity of normal tissue) involving dCK and dCMPD suggesting chemotherapy with 5-fluorodeoxycytidine (5-FdC) alone or in combination with thymidine plus deoxytetra-hydrouridine, or with the radiosensitizer, 5-chlorodeoxycytidine (5-CldC) plus tetrahydrouridine (H4U). Among patients with colon (19) and pancreatic tumors (40), 53 and 68%, respectively, displayed T/N values >4 for CD suggesting chemotherapy with 5-FdC, 4-N-methylamino-5-FdC, 5-trifluoromethyldeoxycytidine and radiosensitization with 5- CldC, 4-N-methylamino-5-CldC, 5-iododeoxycytidine and 5-bromodeoxycytidine. The percent of patients with tumors with a T/N value >4 for U/CK in lung (72), colon (23) and breast (28) was 47, 61 and 68, respectively, suggesting zebularine (plus thymidine) treatment for tumors involving gene silencing. Evidence is presented that the 4-N-alkylamino-dC substituted nucleosides and those with large 5-substitutions are activated only via CD to thymidine kinase (TK) using end-points of cytotoxicity and/or radiosensitization: H4U, the inhibitor of CD is an antagonist, cells with low CD or no TK are resistant to the analogs, the end points are indifferent to the dCK status of cells, they are poor substrates for dCK and good substrates for CD, whereas 5-FdC and 5-CldC are good substrates for both enzymes. The analogs present opportunities for Collateral Sensitivity for 5-azacytidine and gemcitabine resistant tumors.

KW - Activation of prodrugs

KW - Chemotherapy

KW - Cytidine deaminase

KW - DCkinase

KW - DCMPdeaminase

KW - Pyrimidine nucleoside analogs

KW - Radiosensitization

KW - Uridine/cytidine kinase

UR - http://www.scopus.com/inward/record.url?scp=85011075589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011075589&partnerID=8YFLogxK

U2 - 10.2174/1871520616666161013145853

DO - 10.2174/1871520616666161013145853

M3 - Article

VL - 17

SP - 250

EP - 264

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 2

ER -